Related Experiment Video
Updated: Jul 28, 2026

Kinetics of Lagging-strand DNA Synthesis In Vitro by the Bacteriophage T7 Replication Proteins
Published on: February 25, 2017
Repair of topoisomerase-mediated DNA damage in bacteriophage T4
1Departments of Microbiology and Biochemistry, Duke University Medical Center, Durham, NC 27710, USA.
Abstract:
Type II topoisomerase inhibitors are used to treat both tumors and bacterial infections. These inhibitors stabilize covalent DNA-topoisomerase cleavage complexes that ultimately cause lethal DNA damage. A functional recombinational repair apparatus decreases sensitivity to these drugs, suggesting that topoisomerase-mediated DNA damage is amenable to such repair. Using a bacteriophage T4 model system, we have developed a novel in vivo plasmid-based assay that allows physical analysis of the repair products from one particular topoisomerase cleavage site. We show that the antitumor agent 4'-(9-acridinylamino)methanesulphon-m-anisidide (m-AMSA) stabilizes the T4 type II topoisomerase at the strong topoisomerase cleavage site on the plasmid, thereby stimulating recombinational repair. The resulting m-AMSA-dependent repair products do not form in the absence of functional topoisomerase and appear at lower drug concentrations with a drug-hypersensitive topoisomerase mutant. The appearance of repair products requires that the plasmid contain a T4 origin of replication. Finally, genetic analyses demonstrate that repair product formation is absolutely dependent on genes 32 and 46, largely dependent on genes uvsX and uvsY, and only partly dependent on gene 49. Very similar genetic requirements are observed for repair of endonuclease-generated double-strand breaks, suggesting mechanistic similarity between the two repair pathways.
Insights
Type II topoisomerase inhibitors like m-AMSA stimulate recombinational repair of DNA damage. Bacteriophage T4 assays reveal specific gene dependencies for this repair pathway, similar to double-strand break repair.
Area of Science:
- Molecular Biology
- Genetics
- Biochemistry
Background:
- Type II topoisomerase inhibitors are crucial in cancer and bacterial infection treatments.
- These drugs induce lethal DNA damage by stabilizing DNA-topoisomerase cleavage complexes.
- Recombinational repair pathways can reduce sensitivity to these agents, indicating DNA damage repairability.
Purpose of the Study:
- To develop a novel in vivo plasmid-based assay for analyzing topoisomerase-mediated DNA repair products.
- To investigate the role of the antitumor agent m-AMSA in stimulating recombinational repair.
- To elucidate the genetic requirements for repairing topoisomerase-induced DNA damage.
Main Methods:
- Utilized a bacteriophage T4 model system with a plasmid-based assay.
- Physically analyzed repair products at a specific topoisomerase cleavage site.
- Performed genetic analyses to determine gene dependencies for repair product formation.
Main Results:
- The antitumor agent m-AMSA stabilizes T4 type II topoisomerase, stimulating recombinational repair at a specific plasmid site.
- m-AMSA-dependent repair products require functional topoisomerase and are observed with a drug-hypersensitive mutant.
- Repair product formation necessitates a T4 origin of replication and shows specific dependencies on T4 genes (32, 46, uvsX, uvsY, 49).
Conclusions:
- Recombinational repair is stimulated by type II topoisomerase inhibitors like m-AMSA.
- The identified genetic requirements for repairing topoisomerase-induced DNA damage are similar to those for repairing endonuclease-generated double-strand breaks.
- This suggests a mechanistic overlap between these DNA repair pathways.
Related Concept Videos
Nucleotide Excision Repair
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. Type I...
Translesion DNA Polymerases
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
Homologous Recombination
Viral Replication: Lytic Cycle
DNA Bacteriophages

